Current and historical daily PE Ratio for Alnylam Pharmaceuticals Inc (
BSP:A1LN34
) from 2020 to May 30 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Alnylam Pharmaceuticals stock (BSP:A1LN34) PE ratio as of May 30 2024 is 0.
More Details
Alnylam Pharmaceuticals Inc (BSP:A1LN34) PE Ratio (TTM) Chart
Alnylam Pharmaceuticals Inc (BSP:A1LN34) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 945
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Alnylam Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-31 | At Loss | 2024-03-28 | At Loss |
| 2024-05-29 | At Loss | 2024-03-27 | At Loss |
| 2024-05-28 | At Loss | 2024-03-26 | At Loss |
| 2024-05-27 | At Loss | 2024-03-25 | At Loss |
| 2024-05-24 | At Loss | 2024-03-22 | At Loss |
| 2024-05-23 | At Loss | 2024-03-21 | At Loss |
| 2024-05-22 | At Loss | 2024-03-20 | At Loss |
| 2024-05-21 | At Loss | 2024-03-19 | At Loss |
| 2024-05-20 | At Loss | 2024-03-18 | At Loss |
| 2024-05-17 | At Loss | 2024-03-15 | At Loss |
| 2024-05-16 | At Loss | 2024-03-14 | At Loss |
| 2024-05-15 | At Loss | 2024-03-13 | At Loss |
| 2024-05-14 | At Loss | 2024-03-12 | At Loss |
| 2024-05-13 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
Alnylam Pharmaceuticals Inc (BSP:A1LN34) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : BRA1LNBDR003
Share Class Description:
BSP:A1LN34: BRDRCompare
Compare
Traded in other countries / regions
ALNY.USAALNY.Mexico0HD2.UKDUL.GermanyA1LN34.Brazil IPO Date
2020-10-13Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers